CN111214633A - Formula for treating infectious hepatitis B - Google Patents
Formula for treating infectious hepatitis B Download PDFInfo
- Publication number
- CN111214633A CN111214633A CN202010157031.3A CN202010157031A CN111214633A CN 111214633 A CN111214633 A CN 111214633A CN 202010157031 A CN202010157031 A CN 202010157031A CN 111214633 A CN111214633 A CN 111214633A
- Authority
- CN
- China
- Prior art keywords
- formulation
- root
- rhizome
- chinese
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005252 hepatitis A Diseases 0.000 title claims abstract description 25
- 208000037319 Hepatitis infectious Diseases 0.000 title claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 11
- 235000011202 Angiopteris lygodiifolia Nutrition 0.000 claims abstract description 11
- 244000236521 Bupleurum rotundifolium Species 0.000 claims abstract description 11
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 claims abstract description 11
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 11
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 11
- 241000723185 Cyathea Species 0.000 claims abstract description 11
- 241000123589 Dipsacus Species 0.000 claims abstract description 11
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 11
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 11
- 241000329195 Sparganium erectum Species 0.000 claims abstract description 11
- 241000316342 Taxillus Species 0.000 claims abstract description 11
- 241000270666 Testudines Species 0.000 claims abstract description 11
- 241000270708 Testudinidae Species 0.000 claims abstract description 11
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims abstract description 11
- 235000019509 white turmeric Nutrition 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005303 weighing Methods 0.000 claims abstract description 10
- 239000009636 Huang Qi Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims description 17
- 240000000233 Melia azedarach Species 0.000 claims description 7
- 240000001341 Reynoutria japonica Species 0.000 claims description 7
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 240000006766 Cornus mas Species 0.000 claims description 4
- 244000163122 Curcuma domestica Species 0.000 claims description 4
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 4
- 229940107666 astragalus root Drugs 0.000 claims description 4
- 235000003373 curcuma longa Nutrition 0.000 claims description 4
- 235000013976 turmeric Nutrition 0.000 claims description 4
- 244000164480 Curcuma aromatica Species 0.000 claims description 3
- 235000003398 Curcuma aromatica Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 abstract description 15
- 208000002672 hepatitis B Diseases 0.000 abstract description 15
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 9
- 239000000969 carrier Substances 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine formula, in particular to a formula for treating infectious hepatitis B, which comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome; the invention also discloses a preparation method of the formula for treating infectious hepatitis B, which comprises the steps of weighing, raw material treatment, water decoction and the like. The invention has reasonable formula, can be applied to patients who clinically test hepatitis B, whether major three positive, minor three positive, virus carriers or patients who are treated repeatedly, has the hepatitis A cure rate of more than 95 percent, has the hepatitis B cure improvement rate of 75 percent, is rarely seen in patients who are converted into the liver cirrhosis through normal treatment, and is also suitable for patients with early liver cirrhosis.
Description
Technical Field
The invention relates to a traditional Chinese medicine formula, in particular to a formula for treating infectious hepatitis B.
Background
Infectious hepatitis b is an infectious disease mainly caused by hepatitis b virus, and mainly caused by liver diseases. Clinically, the symptoms of anorexia, nausea, epigastric discomfort, liver pain and hypodynamia are mainly manifested. Some patients may have jaundice fever and hepatomegaly with impaired liver function. Some patients can become chronic, even develop cirrhosis of the liver, and a few can develop liver cancer.
Infectious hepatitis B also belongs to the areas of hypochondriac pain, liver distension and the like in the traditional Chinese medicine, and is mainly caused by deficiency of vital qi of viscera such as spleen and stomach, weakened resistance and accumulation of damp-heat evil and toxin in the spleen and stomach. At present, hepatitis B virus carriers account for about fifteen percent of national population, and the health and rehabilitation system of people in China is seriously influenced.
The former thinks that: when moving, blood is transported to all meridians, and when still, blood is collected in the liver. From the analysis of the blood circulation of the liver, it is composed of the hepatic artery and the portal vein which collects the venous blood of the digestive tract in the abdominal cavity. When the blood vessel is relaxed, a larger amount of blood can be contained, and when the blood vessel is contracted, the stored blood can be output to participate in circulation. The liver is one of the special organs of the human blood reservoir, since it has the role of participating in regulating the amount of blood circulating throughout the body. The traditional Chinese medicine also considers that: the liver qi has the physiological functions of dredging, relaxing and regulating. When the liver functions normally, qi flow is smooth, meridians are passed, and the activities of viscera and organs are normal. It follows that the hepatic peptide function it is likely to contain is an aspect of hemodynamics. If the liver fails to function normally, stagnation of liver qi will occur, resulting in qi stagnation and blood stasis.
Infectious hepatitis B is characterized by slight onset and is not found by people or is found by people at all. Most patients are known at the time of physical examination. However, it develops rapidly, and some patients who have alcohol addiction, if they are not treated in time, they are most likely to become liver cirrhosis, even liver cancer. Therefore, once the hepatitis B disease is found, the treatment must be performed quickly. Until there is no clinical diagnosis, hepatitis B deoxyribonucleic acid (N <1000c0 Py/m).
Hepatitis B causes the dysfunction of liver blood storage and catharsis and the reconstruction of liver tissue structure, and under the mutual influence, the liver cirrhosis, which is the liver cancer, is finally formed due to the qi stagnation and blood stasis to the tunnel congestion.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a formula for treating infectious hepatitis B, which is environment-friendly, stable and efficient.
In order to achieve the purpose of the invention, the invention adopts the technical scheme that:
a formula for treating infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome.
Preferably, the formula for treating the infectious hepatitis B further comprises the following components in parts by weight: 12 g of curcuma aromatica, 12 g of szechwan chinaberry fruit and 30 g of tuber fleeceflower stem.
Preferably, the formula for treating the infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome.
Preferably, the formula for treating the infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 12 g of turmeric root-tuber, 12 g of szechwan chinaberry fruit, 30 g of glabrous greenbrier rhizome, 30 g of astragalus root, 10 g of American ginseng, 50g of dogwood fruit, 30 g of Chinese taxillus twig, 15 g of dipsacus root, 15 g of east Asian tree fern rhizome and 30 g of tuber fleeceflower stem.
Preferably, the finished product is one of decoction, pill or paste.
Preferably, the preparation method of the decoction comprises the following steps:
(1) weighing according to the weight ratio;
(2) decocting carapax Trionycis, carapax et Plastrum Testudinis and radix Panacis Quinquefolii with water for one hour, respectively, decocting radix Panacis Quinquefolii with slow fire, cleaning other materials, and draining;
(3) adding carapax Trionycis, carapax et Plastrum Testudinis, and radix Panacis Quinquefolii into a pot, decocting in water for one hour, and filtering to obtain decoction.
Preferably, the preparation method of the pill comprises the following steps:
(1) weighing according to the weight ratio;
(2) grinding the above materials into powder, sieving, and making into watered pill or honeyed pill.
Preferably, the preparation method of the paste comprises the following steps:
(1) weighing according to the weight ratio;
(2) soaking the raw materials in clear water, and decocting with slow fire to obtain unguent.
The invention has the beneficial effects that: the prescription is reasonable, and the medicine can be applied to patients who clinically test hepatitis B, whether major three positive, minor three positive, virus carriers or patients who are treated repeatedly, the cure rate of hepatitis A is more than 95%, the cure improvement rate of hepatitis B can reach 75%, patients who change into liver cirrhosis after normal treatment are rare, and the medicine is also suitable for patients with early liver cirrhosis.
Detailed Description
In order to make the content of the present invention more clearly understood, the technical solutions in the embodiments of the present invention will be clearly and completely described below.
A formula for treating infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome.
Preferably, the formula for treating the infectious hepatitis B further comprises the following components in parts by weight: 0-12 g of curcuma aromatica, 0-12 g of szechwan chinaberry fruit and 0-30 g of tuber fleeceflower stem.
The first embodiment is as follows:
a formula for treating infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 12 g of turmeric root-tuber, 12 g of szechwan chinaberry fruit, 30 g of glabrous greenbrier rhizome, 30 g of astragalus root, 10 g of American ginseng, 50g of dogwood fruit, 30 g of Chinese taxillus twig, 15 g of teasel root and 15 g of east Asian tree fern rhizome.
Example two:
a formula for treating infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome.
Example three:
a formula for treating infectious hepatitis B comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 12 g of turmeric root-tuber, 12 g of szechwan chinaberry fruit, 30 g of glabrous greenbrier rhizome, 30 g of astragalus root, 10 g of American ginseng, 50g of dogwood fruit, 30 g of Chinese taxillus twig, 15 g of dipsacus root, 15 g of east Asian tree fern rhizome and 30 g of tuber fleeceflower stem.
The finished medicament of the invention is one of decoction, pills or paste.
The preparation method comprises the following steps: the preparation method of the decoction comprises the following steps:
(1) weighing according to the weight ratio;
(2) decocting carapax Trionycis, carapax et Plastrum Testudinis and radix Panacis Quinquefolii with water for one hour, respectively, decocting radix Panacis Quinquefolii with slow fire, cleaning other materials, and draining;
(3) adding carapax Trionycis, carapax et Plastrum Testudinis, and radix Panacis Quinquefolii into a pot, decocting in water for one hour, and filtering to obtain decoction.
The application method of the decoction comprises the following steps: the oral preparation is taken 50g in one dose, one dose is taken every day, and the oral preparation is taken twice in the morning and at night.
The second preparation method comprises the following steps: the preparation method of the pill comprises the following steps:
(1) weighing according to the weight ratio;
(2) grinding the raw materials into powder respectively, sieving with a 120-mesh sieve, and making into watered pill or honeyed pill, wherein each pill is about 0.5 g.
The application method of the pill comprises the following steps: the medicine is taken orally, 5g of the medicine is taken as one dose (10 granules), and the medicine is taken twice in the morning and evening.
The preparation method comprises the following steps: the preparation method of the ointment comprises the following steps:
(1) weighing according to the weight ratio;
(2) soaking the raw materials in clear water, and decocting with slow fire to obtain unguent.
The application method of the ointment comprises the following steps: the medicine is taken orally, 5g of the medicine is taken as one dose every day, and the medicine is taken twice in the morning and at night.
The invention has the beneficial effects that: the prescription is reasonable, and the medicine can be applied to patients who clinically test hepatitis B, whether major three positive, minor three positive, virus carriers or patients who are treated repeatedly, the cure rate of hepatitis A is more than 95%, the cure improvement rate of hepatitis B can reach 75%, patients who change into liver cirrhosis after normal treatment are rare, and the medicine is also suitable for patients with early liver cirrhosis.
The effect of the present invention will be described below with reference to the cases in recent years:
case one:
patient Mr. King, age 26, chief complaints: the pain in the right upper abdomen has been relieved in three years, sometimes relieved and heavy, and the patient keeps doing light work, feels that the hypochondriac pain is aggravated in the last week, the nucleus is severe, and is associated with stomach glue swelling, bitter taste in mouth, poor appetite, weakness in limbs, lusterless and dark complexion, scanty and dark urine, yellow and thick tongue coating, and wiry, thready and rapid pulse. The serum test reports "big three positive", the hepatitis B DINA result is 4100Cc0py/m, the pulse is wiry and thin, and the tongue is red. The syndrome includes dampness-heat accumulation in the liver collaterals, obstruction of the liver function, qi stagnation and blood stasis, and liver-spleen yin deficiency.
For treating soothing liver, regulating qi, strengthening spleen, eliminating dampness, promoting blood circulation, removing blood stasis, tonifying liver and kidney, and strengthening vital qi; when the finished product prepared by the invention is used for treatment, 7 doses of the prescription in the first embodiment of the decoction form are obtained through first diagnosis.
And B, diagnosis: hypochondriac pain is relieved, and tapping pain in the liver area is obviously relieved. For a slight increase in food intake, 7 doses of the second prescription example in the form of pills are prepared by removing radix Curcumae and fructus Toosendan from the original prescription.
Three diagnoses: hypochondriac pain has been relieved, scanty and yellow urine, lusterless complexion, smooth and thin coating. After the treatment of the disease, the symptoms are improved, 7 doses of the prescription in the first embodiment of the decoction form are prepared.
Four diagnosis: all syndromes are removed and worked like the normal one. The first example of decoction form is that 7 doses of the prescription are used for strengthening the curative effect, and the test is recommended to be performed again.
Five diagnoses: the serum assay is reported as: the five hepatitis B patients are positive and the other four patients are negative; hepatitis B DNA result n <1000 cPpy/m. Order it to take five bottles of liver protecting tablets, and take the diet to abstain from alcohol.
Case two:
the patient is born before age 33, and the toxic hepatitis B has been suffered for three years. The main complaints are: dull pain in the right upper abdomen, even generation of qi, mental fatigue and anorexia. Dark and lusterless face, wiry and thready pulse, thin and red tongue coating. The five items of serum hepatitis B are tested as 'big three positive'. The syndrome refers to the condition of liver-qi failing to disperse and liver-kidney yin deficiency.
For treatment of soothing liver, regulating qi, strengthening spleen and kidney; the finished product prepared by the invention is used for treatment, and 7 doses of the prescription in the form of pill are prepared for the first diagnosis.
And B, diagnosis: the pulse turns into a string and is small and smooth, the hypochondriac pain is already relieved, and 7 doses of the prescription in the first example of the pill form are prepared; for poor sleep, 30 g of tuber fleeceflower stem is added, and thirty-five doses of the formula are added in the third embodiment in the form of paste. The five hepatitis B items are all turned to negative and the hepatitis B deoxybranched ribonucleic acid (ON) is less than 1000 COPy/m.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (8)
1. The formula for treating infectious hepatitis B is characterized by comprising the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome.
2. The formulation of claim 1, wherein said formulation is for the treatment of infectious hepatitis B: the formula for treating the infectious hepatitis B further comprises the following components in parts by weight: 0-12 g of curcuma aromatica, 0-12 g of szechwan chinaberry fruit and 0-30 g of tuber fleeceflower stem.
3. The formulation of claim 2, wherein said formulation is selected from the group consisting of: comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 30 g of glabrous greenbrier rhizome, 30 g of membranous milkvetch root, 10 g of American ginseng, 50g of common macrocarpium fruit, 30 g of Chinese taxillus twig, 15 g of himalayan teasel root and 15 g of east Asian tree fern rhizome.
4. The formulation of claim 2, wherein said formulation is selected from the group consisting of: comprises the following components in parts by weight: 12 g of common burreed rhizome, 12 g of zedoary, 15 g of raw turtle shell, 15 g of raw tortoise shell, 12 g of Chinese angelica, 9 g of Chinese thorowax root, 12 g of turmeric root-tuber, 12 g of szechwan chinaberry fruit, 30 g of glabrous greenbrier rhizome, 30 g of astragalus root, 10 g of American ginseng, 50g of dogwood fruit, 30 g of Chinese taxillus twig, 15 g of dipsacus root, 15 g of east Asian tree fern rhizome and 30 g of tuber fleeceflower stem.
5. The formulation of claim 1, wherein said formulation is for the treatment of infectious hepatitis B: the product is one of decoction, pill or paste.
6. The formulation of claim 5, wherein said formulation is selected from the group consisting of: the preparation method of the decoction comprises the following steps:
(1) weighing according to the weight ratio;
(2) decocting carapax Trionycis, carapax et Plastrum Testudinis and radix Panacis Quinquefolii with water for one hour, respectively, decocting radix Panacis Quinquefolii with slow fire, cleaning other materials, and draining;
(3) adding carapax Trionycis, carapax et Plastrum Testudinis, and radix Panacis Quinquefolii into a pot, decocting in water for one hour, and filtering to obtain decoction.
7. The formulation of claim 5, wherein said formulation is selected from the group consisting of: the preparation method of the pill comprises the following steps:
(1) weighing according to the weight ratio;
(2) grinding the above materials into powder, sieving, and making into watered pill or honeyed pill.
8. The formulation of claim 5, wherein said formulation is selected from the group consisting of: the preparation method of the ointment comprises the following steps:
(1) weighing according to the weight ratio;
(2) soaking the raw materials in clear water, and decocting with slow fire to obtain paste.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010157031.3A CN111214633A (en) | 2020-03-09 | 2020-03-09 | Formula for treating infectious hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010157031.3A CN111214633A (en) | 2020-03-09 | 2020-03-09 | Formula for treating infectious hepatitis B |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111214633A true CN111214633A (en) | 2020-06-02 |
Family
ID=70812096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010157031.3A Pending CN111214633A (en) | 2020-03-09 | 2020-03-09 | Formula for treating infectious hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111214633A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418679A (en) * | 2002-11-27 | 2003-05-21 | 张慧芳 | Medicine compositions for treating hepatitis, and its prepn. method |
| CN101406675A (en) * | 2008-12-08 | 2009-04-15 | 姜彬 | Medicine for treating hepatitis B |
| CN102166329A (en) * | 2010-03-17 | 2011-08-31 | 慕少英 | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof |
| CN102302732A (en) * | 2011-08-20 | 2012-01-04 | 刘华 | Liver-soothing and blood-stasis-removing granules and preparation method thereof |
| CN105561146A (en) * | 2014-10-14 | 2016-05-11 | 张陈 | Traditional Chinese medicine formula for treatment of hypochondriac pain type hepatitis B |
-
2020
- 2020-03-09 CN CN202010157031.3A patent/CN111214633A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1418679A (en) * | 2002-11-27 | 2003-05-21 | 张慧芳 | Medicine compositions for treating hepatitis, and its prepn. method |
| CN101406675A (en) * | 2008-12-08 | 2009-04-15 | 姜彬 | Medicine for treating hepatitis B |
| CN102166329A (en) * | 2010-03-17 | 2011-08-31 | 慕少英 | Medicine for treating leukopenia caused by chronic hepatitis B or interferon and preparation method thereof |
| CN102302732A (en) * | 2011-08-20 | 2012-01-04 | 刘华 | Liver-soothing and blood-stasis-removing granules and preparation method thereof |
| CN105561146A (en) * | 2014-10-14 | 2016-05-11 | 张陈 | Traditional Chinese medicine formula for treatment of hypochondriac pain type hepatitis B |
Non-Patent Citations (6)
| Title |
|---|
| 刘焕先: "化瘀健脾软肝丸抗肝硬化的疗效观察", 《光明中医》 * |
| 周德生等: "《大剂量中药临床应用》", 30 September 2016, 山西科学技术出版社 * |
| 张如棉等: "康氏系列方联合保肝治疗慢性乙型肝炎的疗效观察", 《湖北中医杂志》 * |
| 张静宜: "慢性病毒性乙型肝炎治疗体会", 《中国医药学报》 * |
| 秦春红等: "益气活血方治疗乙肝肝硬化57例", 《光明中医》 * |
| 耿呈祥: "三棱莪术汤治疗传染性乙型肝炎的临床经验", 《HTTPS://WENKU.BAIDU.COM/VIEW/2E8AE269AAEA998FCC220EA4.HTML》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102038758A (en) | Rheumatism preparation used for treating rheumatism | |
| CN103948782B (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN111150799A (en) | Composition for preventing and treating hyperuricemia and gout as well as preparation method and application thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN104800771A (en) | Traditional Chinese medicine preparation for treating children sleep terror disorder and preparation method thereof | |
| CN111214633A (en) | Formula for treating infectious hepatitis B | |
| CN103083590A (en) | Medicine used for treating decompensated liver cirrhosis, and preparation method thereof | |
| CN102641424B (en) | Chinese prepared medicine mixture for treating acute urticaria | |
| CN104510972A (en) | Traditional Chinese medicinal composition for treating asthma and preparation method of traditional Chinese medicinal composition | |
| CN100388942C (en) | Leukemia treating Chinese medicine composition and its prepn | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN102641422B (en) | Chinese patent medicine for treating acute urticaria | |
| CN102631481B (en) | Chinese medicinal preparation for treating viral hepatitis | |
| CN107854588A (en) | A kind of Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN102631483A (en) | Traditional Chinese medicine (TCM) for treating acute urticaria | |
| CN102631648A (en) | Chinese patent medicine for treating acute urticaria | |
| CN104771705A (en) | Traditional Chinese medicine preparation for treating chronic nephritis | |
| CN116549579A (en) | Preparation method of drug for treating uremia | |
| CN105288066A (en) | Prescription for treating atherosclerosis and preparation method thereof | |
| CN105287829A (en) | Chinese herb composition for treating nephritic syndrome and preparation method | |
| CN113181302A (en) | Traditional Chinese medicine for treating nephritis | |
| CN1194722C (en) | Shugan Zhitong soft extract for treating hepatitis | |
| CN104258204B (en) | A kind of Chinese medicine composition and its application in treatment nephrotic syndrome medicine is prepared | |
| CN118304369A (en) | Traditional Chinese medicine composition for treating phlegm stagnation type hyperuricemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200602 |
|
| RJ01 | Rejection of invention patent application after publication |